Clinical Trials Browser

Phase 1/2 × Neuroendocrine Tumors × cabozantinib × Clear all

NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors